Radiation and immunotherapy with chemo for nose and throat cancer
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests combining low-dose radiation with an immunotherapy drug (toripalimab) and chemotherapy for people whose nose and throat cancer has come back or spread. The goal is to see if this combination works better than standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have a specific type of nose and throat cancer called non-keratinizing nasopharyngeal carcinoma.
- You are in generally good health (able to do daily activities without significant help).
- Your cancer has either just spread to other parts of the body or came back at least 12 months after finishing initial treatment.
- You haven't had radiation, chemotherapy, or immunotherapy for this new spread or return of cancer before.
- Your blood counts, liver, kidney, and heart function are within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a targeted radiation therapy, combined with the immunotherapy drug toripalimab before and after treatment, can reduce side effects while still effectively treating nasopharyngeal cancer. It is for patients with certain tumor sizes or stages who have not had prior neck radiation or immunotherapy.
This trial tests a combination of an EGFR antibody, a PD-1 inhibitor, and chemotherapy for people with nasopharyngeal cancer that has returned or spread after initial treatment. The goal is to see if this new mix can help shrink tumors or slow the disease.
This trial tests if adding an immunotherapy drug (PD-1 inhibitor) after standard induction chemotherapy helps keep advanced nasopharyngeal cancer from coming back. It is for people who have completed 3 cycles of GP chemotherapy combined with a PD-1 inhibitor and have not had their cancer progress.
This trial tests if adding an immunotherapy drug (toripalimab) to standard chemotherapy works better than chemotherapy alone for children and teens with advanced nasopharyngeal cancer (a type of nose cancer). The goal is to improve outcomes for newly diagnosed patients.
This trial tests a combination of low-dose radiation, chemotherapy, and immunotherapy for nasopharyngeal cancer that has spread to the liver. It aims to see if this approach can help shrink tumors and improve outcomes.
This trial tests a combination of a new immunotherapy (QL1706) plus standard chemoradiation for people with advanced nasopharyngeal cancer that hasn't spread to distant organs. The goal is to see if adding this drug helps control the cancer better than standard treatment alone.
Hear when a new Nasopharyngeal Cancinoma (NPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.